Exanta (ximelagatran), a new anticoagulant and the first oral treatment in the new class of direct thrombin inhibitors (DTIs), was launched in Germany in its first indication- the prevention of venous thromboembolic events (VTE) in elective hip or knee replacement surgery (orthopaedic surgery), a release from Astrazeneca said.
Exanta is the first oral anticoagulant since the introduction of warfarin almost 60 years ago. It was developed to provide a solution to the significant unmet medical need for a new, predictable and well-tolerated oral therapy for patients at risk of thrombosis, one of the major causes of cardiovascular morbidity and mortality in the developed world.
The prevention of VTE in orthopaedic surgery is an important proof of principle indication for Exanta and follows the successful completion of the EU Mutual Recognition Process for this indication in May 2004. Patients are particularly at risk of thrombosis following orthopaedic surgery, with more than half developing VTE in the absence of preventative anticoagulant treatment. Whilst effective treatments are available, no treatment regimen to date has successfully balanced efficacy and bleeding risk with oral dosing.
The approved label in the EU for Exanta in this indication involves an early postoperative start of treatment, with initial injectable dosing administered 4 - 8 hours after the completion of surgery, followed by oral Exanta 24mg twice daily for up to 11 days. This approach supports the increasing use of postoperative initiation of VTE preventative treatment in clinical practice across Europe, and also enables oral treatment to be easily continued following discharge from hospital.
"Clinical studies have shown the potential that Exanta offers as a new approach to the prevention and management of thrombosis. I am excited that this new oral anticoagulant is now becoming available for orthopaedic surgery patients" commented professor Bengt Eriksson, Department of Orthopaedics, Sahlgrenska/Ostra University Hospital, Gothenburg, Sweden, and lead investigator in European orthopaedic surgery study programme.
Exanta has been the subject of the largest clinical study programme in anticoagulation to date, involving around 30,000 patients. It is under regulatory review in the EU for key chronic use indications including the prevention of stroke and other thromboembolic complications associated with atrial fibrillation and the treatment of venous thromboembolism (VTE).
"Exanta is an innovative new approach to the treatment and prevention of thrombosis," commented Dr Hamish Cameron, vice president, head of Exanta, AstraZeneca.
As an oral Direct Thrombin Inhibitor, Exanta benefits from a unique mode of action that enables predictable protection against the risk of thrombotic events, administration as a fixed oral dose, a rapid onset and offset of action and low potential for food and drug interactions. Importantly, coagulation monitoring is also not necessary in treatment with Exanta.
The worldwide market for anticoagulants is around $4 billion and growing at 13 per cent annually, while the worldwide anti-thrombotic market is around $12 billion, growing at 15 per cent annually.